Department of Urology, Health Sciences University, Umraniye Training & Research Hospital, Istanbul, Turkey.
Department of Urology, Health Sciences University, Umraniye Training & Research Hospital, Istanbul, Turkey.
Actas Urol Esp (Engl Ed). 2022 Jun;46(5):293-300. doi: 10.1016/j.acuroe.2021.12.003. Epub 2022 Feb 24.
We aim to compare the first year oncological and functional outcomes of Retzius-sparing robot-assisted radical prostatectomy (Rs-RARP) and standard robot-assisted radical prostatectomy (RARP).
Eighty-eight patients who underwent robotic radical prostatectomy between 2018-2019 were included. We compared the minimum one-year follow-up results of patients who underwent Rs-RARP or RARP in terms of oncological and functional outcomes. Potency was assessed with the Sexual Health Inventory for Men (SHIM) score and was defined as an erection sufficient for penetration. Continence was defined as the absence of urinary incontinence with no safety pad. Patients were evaluated in the first month of follow-up and subsequently, every three months.
Forty-six patients in Rs-RARP and 42 patients in the RARP group were enrolled. Catheter removal time was shorter in the Rs-RARP group (12 vs. 14 days, p = 0.001). At the 1st month visit, 41 patients (%89) were continent (no pads) in the Rs-RARP group while 25 patients (%59) were continent in the RARP group (p = 0.001). Patients who underwent Rs-RARP achieved faster recovery of urinary continence (Log-rank, p = 0.001). After one year of follow-up, 43 patients (93%) in Rs-RARP group and 38 patients (90%) in RARP group were continent (p = 0.6). Potency rates were 38.7% in Rs-RARP and 34.4% in RARP group (p = 0.28). There were no cases of biochemical recurrence in any group.
Rs-RARP is a feasible technique, providing early return of continence. However, overall continence rates were similar at the end of the one-year follow-up.
我们旨在比较保留耻骨后间隙的机器人辅助根治性前列腺切除术（Rs-RARP）和标准机器人辅助根治性前列腺切除术（RARP）的第一年肿瘤学和功能结果。
纳入了 2018-2019 年间接受机器人根治性前列腺切除术的 88 例患者。我们比较了接受 Rs-RARP 或 RARP 治疗的患者在肿瘤学和功能结果方面的至少一年的随访结果。勃起功能通过男性性功能健康问卷（SHIM）评分来评估，定义为足以进行插入的勃起。控尿定义为无尿失禁且无需使用尿垫。患者在随访的第一个月进行评估，随后每三个月评估一次。
Rs-RARP 组有 46 例患者，RARP 组有 42 例患者。Rs-RARP 组的导尿管拔除时间更短（12 天比 14 天，p=0.001）。在第一个月就诊时，Rs-RARP 组有 41 例（89%）患者达到控尿（无尿垫），而 RARP 组有 25 例（59%）患者达到控尿（p=0.001）。接受 Rs-RARP 的患者更快恢复尿控（对数秩检验，p=0.001）。在一年的随访后，Rs-RARP 组有 43 例（93%）患者和 RARP 组有 38 例（90%）患者达到控尿（p=0.6）。Rs-RARP 组的勃起功能率为 38.7%，RARP 组为 34.4%（p=0.28）。两组均无生化复发病例。
Rs-RARP 是一种可行的技术，可早期恢复控尿。然而，在一年的随访结束时，总体控尿率相似。
